18 / 30
Survival benefit with atezolizumab is observed across all PD-L1 expression subgroups (SP142 assay) and the ITT population, including the PD-L1
negative population (TC0 and IC0)
TC0 and IC0 Subgroup
PD-L1 expression does not
predict OS for Atezolizumab in
metastatic NSCLC: OAK study